文献速递临床试验与 GCP

BCc1与Hep-S纳米螯合基药物联合应用对住院中度COVID-19成年患者IL-6的有益影响:一项随机、双盲、安慰剂对照临床试验

Beneficial effects of the combination of BCc1 and Hep-S nanochelating-based medicines on IL-6 in hospitalized moderate COVID-19 adult patients: a randomized, double-blind, placebo-controlled clinical trial.
PubMed 文献 · Trials · 2023-11-11

本研究为随机双盲安慰剂对照试验,纳入实验室确诊的中度COVID-19住院患者,分为BCc1与Hep-S联合治疗组(N=62)和安慰剂组(N=60)。结果显示,治疗组IL-6平均水平显著下降,研究结束时IL-6下降77%,而安慰剂组上升18%(p<0.05);治疗组TNF-α下降21%,安慰剂组上升31%(p>0.05)。治疗组咳嗽、疲劳及需氧治疗的临床评分改善。

要点

  • BCc1与Hep-S联合治疗组IL-6下降77%,安慰剂组上升18%(p<0.05)。
  • 治疗组TNF-α下降21%,安慰剂组上升31%(p>0.05)。
  • 治疗组咳嗽、疲劳及需氧治疗临床评分改善。

核心结论

  • BCc1与Hep-S联合应用可抑制COVID-19病理生理中重要的IL-6,为免疫调节管理细胞因子风暴综合征提供了有前景的视角。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,纳入实验室确诊的中度COVID-19住院患者,联合治疗组N=62,安慰剂组N=60。

主要发现

  • 治疗组IL-6平均水平显著下降,研究结束时IL-6下降77%,而安慰剂组上升18%(p<0.05)。
  • 治疗组TNF-α水平下降21%,安慰剂组上升31%(p>0.05)。
  • 治疗组咳嗽、疲劳及需氧治疗的临床评分改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the severe forms of COVID-19 and many other infectious diseases, the patients develop a cytokine storm syndrome (CSS) where pro-inflammatory cytokines such as IL-6 and TNF-α play a key role in the development of this serious process. Selenium and iron are two important trace minerals, and their metabolism is tightly connected to immune system function. Numerous studies highlight the role of selenium and iron metabolism changes in the procedure of COVID-19 inflammation. The immunomodulator effect of nanomedicines that are synthesized based on nanochelating technology has been proved in previous studies. In the present study, the effects of the combination of BCc1(with iron-chelating property) and Hep-S (containing selenium) nanomedicines on mentioned cytokines levels in hospitalized moderate COVID-19 patients were evaluated. METHODS: Laboratory-confirmed moderate COVID-19 patients were enrolled to participate in a randomized, double-blind, placebo-controlled study in two separate groups: combination of BCc1 and Hep-S (N = 62) (treatment) or placebo (N = 60) (placebo). The blood samples were taken before medications on day zero, at discharge, and 28 days after consumption to measure hematological and biochemical parameters and cytokine levels. The clinical symptoms of all the patients were recorded according to an assessment questionnaire before the start of the treatment and on days 3 and discharge day. RESULTS: The results revealed that consumption of the nanomedicines led to a significant decrease in the mean level of IL-6 cytokine, and at the end of the study, there was a 77% downward trend in IL-6 in the nanomedicine group, while an 18% increase in the placebo group (p < 0.05). In addition, the patients in the nanomedicines group had lower TNF-α levels; accordingly, there was a 21% decrease in TNF-α level in the treatment group, while a 31% increase in this cytokine level in the placebo was observed (p > 0.05). On the other hand, in nanomedicines treated groups, clinical scores of coughing, fatigue, and need for oxygen therapy improved. CONCLUSIONS: In conclusion, the combination of BCc1 and Hep-S inhibits IL-6 as a highly important and well-known cytokine in COVID-19 pathophysiology and presents a promising view for immunomodulation that can manage CSS. TRIAL REGISTRATION: Iranian Registry of Clinical Trials RCT20170731035423N2 . Registered on June 12, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hafizi M, Kalanaky S, Fakharzadeh S, et al. Beneficial effects of the combination of BCc1 and Hep-S nanochelating-based medicines on IL-6 in hospitalized moderate COVID-19 adult patients: a randomized, double-blind, placebo-controlled clinical trial. Trials. 2023. PMID: 37951972. doi:10.1186/s13063-023-07624-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。